What proprietary (non-generic) treatments are available for NSCLC, and when were they licensed?

Read full text Summarise with VIRAT
Authors: Tripdatabase
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Various proprietary treatments for NSCLC, including Pembrolizumab, Durvalumab, and Cemiplimab, have been licensed, primarily in 2025, targeting specific molecular and clinical patient profiles.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
30 March 2026
Language
EN